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Summary 
Although the etiology of multiple sclerosis (MS) is unknown, there is compelling evidence that 
its pathogenesis is mediated through the immune system. Molecular mimicry, i.e., crossreactivity 
between self-antigens and viral proteins, has been implicated in the initiation of autoimmunity 
and MS. Based on homology to human T cell lymphotropic virus type I (HTLV-I) a novel human 
retrotransposon was cloned and found to constitute an integral part of the coding sequence of 
the human transaldolase gene (TAL-H). TAL-H is a key enzyme of the nonoxidative pentose 
phosphate pathway (PPP) providing ribose-5-phosphate for nucleic acid synthesis and NADPH 
for lipid biosynthesis. Another fundamental function of the PPP is to maintain glutathione at 
a reduced state and, consequently, to protect sulfhydryl groups and cellular integrity from oxygen 
radicals. Immunohistochemical analyses of human brain sections and primary routine brain cell 
cultures demonstrated that TAL is expressed selectively in oligodendrocytes at high levels, possibly 
linked to production of large amounts of lipids as a major component of myelin, and to the 
protection of the vast network of myelin sheaths from oxygen radicals. High-affinity autoantibodies 
to recombinant TAL-H were detected in serum (25/87) and cerebrospinal fluid (15/20) of patients 
with MS. By contrast, TAL-H antibodies were absent in 145 normal individuals and patients 
with other autoimmune and neurological diseases. In addition, recombinant TAL-H stimulated 
proliferation and caused aggregate formation of peripheral blood lymphocytes from patients with 
MS. Remarkable amino acid sequence homologies were noted between TAL-H and core proteins 
of human retroviruses. Presence of crossreactive antigenic epitopes between recombinant TAL-H 
and HTLV-I/human immunodeficiency virus type 1 (HIV-1) gag proteins was demonstrated 
by Western blot analysis. The results suggest that molecular mimicry between viral core proteins 
and TAL-H may play a role in breaking immunological tolerance and leading to a selective destruction 
of oligodendrocytes in MS. 
M 
ultiple sclerosis  (MS) 1 lesions are characterized by a 
progressive loss of oligodendrocytes and demyelination 
in the white matter of the central nervous system (CNS) (1). 
In the acute stage of disease,  lesions contain macrophages, 
T  cells, and immunoglobulin deposits suggesting that the 
demyelination process is mediated by the immune system. 
The inflammatory picture of early lesions, which is followed 
1 Abbreviations used in this paper: ADTG, Ala-Asp-Thr-Gly;  ATL, adult T 
cell leukemia;  CNS, central  nervous  system;  CP, chronic  progressive;  CSF, 
cerebrospinal  fluid; ECG, essential  cryoglobulinemia;  GFAP, glial fibrillary 
acidic protein; GST, glutathione-S-transferase;  HTLV-I, human T cell 
lymphotropic  virus  type  I; MBP, myelin  basic  protein;  MS, multiple  sclerosis; 
PPP, pentose  phosphate  pathway;  R/R, relapsing/remitting;  SJS, Sjogren's 
syndrome;  SLE, systemic  lupus erythematosis;  TAL, transaldolase;  TAL-H, 
human TAL. 
by a progressive gliosis,  suggested that the pathological pro- 
cess  may be  initiated  by infectious agents  and  then  self- 
perpetuated by a crossreactive autoimmune process (2-7). 
Whereas a number of myelin-derived structural proteins were 
shown to elicit MS-like disease in animal models, the antigen(s) 
driving this self-destructive process, which could account for 
pathogenesis of the human disease,  has not been identified 
(1). Studies on relapsing experimental allergic encephalomyelitis 
(EAE) have shown that different encephalitogenic molecules 
or epitopes within them are selected, which is compatible 
with the heterogeneity of the immune response in MS, sug- 
gesting that relapse  episodes are induced by different neu- 
roantigens (8, 9). Nevertheless, oxygen radicals have been sug- 
gested  to  play  a  key  role  in  the  demyelination process. 
Intralesional cytotoxic T cells produce TNF-~ which, in turn, 
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cell death, of oligodendrocytes (10). Macrophages and astro- 
cytes produce nitric oxide, which can also destroy oligoden- 
drocytes via formation of reactive oxygen intermediates (11). 
By contrast, cellular integrity is protected from damage of 
ROI by reduced glutathione which is solely dependent on 
NADPH produced uniquely by pentose phosphate pathway 
(PPP) (12).  The present data provide evidence that a rate- 
limiting enzyme of PPP,  transaldolase (TAL), is expressed 
in an oligodendrocyte-specific manner.  Further, a subset of 
patients with MS has antibodies to TAL in their blood and 
cerebrospinal fluid. Recombinant human transaldolase (TAL- 
H) induces proliferation and aggregate formation of periph- 
eral blood lymphocytes from patients with MS.  Autoanti- 
genic epitopes are contained in a retrotransposon-encoded re- 
gion of the TAL-H gene (13) showing amino acid sequence 
homologies with viral core proteins. This study suggests that 
molecular mimicry inducing autoimmunity to the TAL-H 
protein  could be  involved in  the  selective destruction  of 
oligodendrocytes in MS. 
Materials  and Methods 
Human Sera.  Patients included 95 with MS, 19 with Sjogren's 
syndrome (SJS), 25 with systemic lupus erythematous (SLE), and 
32 with essential cryoglobulinemia (ECG). All patients  satisfied 
the criteria for a definitive diagnosis (14). Sera from 77 healthy sub- 
jects and 24 patients with other neurological diseases were used 
as negative control. Sera of five adult T cell leukemia (ATL) pa- 
tients and a rabbit antibody raised against HTLV-I virion lysate 
were used as human  T  cell lymphotrophic virus type I (HTLV- 
1)-specific antibodies. 
Prokaryotic Expression of Recombinant Protein.  A 157-amino acid 
long NH2-terminal segment of TAbH was expressed in the pEV 
vector system as described earlier (13). Briefly,  a 474-bp EcoRI frag- 
ment, that is, the 4/2 section of the 4/2-4/1 TAbH cDNA, which 
contains an uninterrupted open reading frame, was ligated into the 
pEV  plasmid  vector  and  expressed  in  Escherichia  coli RR1 
[pRK248clts] (15). Construction of the vector is such that an ATG 
codon is placed before the codon corresponding to the first amino 
acid of the mature gene product.  Bacterial cultures were grown 
at 30~  in M9 medium with 0.5% glucose, 10 mM MgSO4, 10 
/~g/ml thiamine,  20 #g/ml  thymine,  10 #g/ml proline,  1 /~M 
CaC12, and 0.5% casamino acids. Expression of the recombinant 
protein was induced by growing the bacteria at 42~  Bacterial 
lysates were resuspended in 1:10  volume of  Laemmli buffer and ana- 
lyzed by SDS-PAGE (16). The full-length TAL-H protein was ex- 
pressed as a fusion protein  with glutathione-S-transferase (GST) 
encoded by pGEX-2T plasmid vector (17). A BgllI site was gener- 
ated by polymerase chain reaction-mediated mutagenesis immedi- 
ately 5' of the first methionine codon of  TAL-H  cDNA (13). Thus, 
a 1,033-nucleotide long BgllI fragment of cDNA clone 4/2-4/1, 
between nucleotide positions 57 and 1,090, respectively,  was cloned 
into the BamHI site of  pGEX-2T, immediately downstream of the 
thrombin cleavage site. Optimum stimulation of expression of the 
recombinant fusion protein was obtained with 1 mM isopropylthio- 
~-galactoside (IPTG) after 2 h. By Western blot analysis of  protein 
lysates, a 66-kD  fusion protein  (38 kD TAL-H +  28 kD GST) 
was detected using antibody 169 (13). A TAL-H/GST fusion pro- 
tein was affinity-purified through binding of GST to glutathion- 
coated agarose beads as specified  by the supplier (Pharmacia LKB, 
Piscataway, NJ). TAL-H protein was cleaved  from GST by 1 NIH 
unit of thrombin  (Sigma Chemical Co., St. Louis, MO) in 1 ml 
of  PBS containing 600/~g fusion protein. TAL-H  protein was sepa- 
rated from the agarose bead-bound GST by centrifugation.  The 
purified fulI-Iength recombinant TAL-H was found to be highly 
functional in the TAL enzyme assay by showing a specific  activity 
of )10 U/rag protein  (13, 18). 
Testing of TAL Enzyme Activity.  TAL enzyme activity was tested 
in the presence  of  3.2 mM D-fructose  6-phosphate, 0.2 mM erythrose 
4-phosphate,  0.1  mM  NADH,  10  #g  c~-glycerophosphate de- 
hydrogenase/triosephosphate isomerase at a 1:6 ratio at room tem- 
perature by continuous absorbance reading at 340 nm for 20 rain 
(18). The assay was conducted in the activity range of 0.001-0.01 
U/ml using yeast TAL as a positive control. All reagents for the 
TAL assay were from Sigma Chemical Co. 
Retroviral Proteins.  Reactivity of TAL-H-specific  antibody 169 
with HIV proteins was investigated by Western blot analysis of 
protein lysates of HIV-l-infected  PBLs. Viral reagents were ob- 
tained from the National  Institutes  of Health (NIH) AIDS Re- 
search and Reference Program. Infectious stock of the strain HIV- 
lnm was harvested from 24-h supernatants of freshly infected H9 
cells  (ATCC CRL-8543; American  Type Culture  Collection 
[ATCC], Roc) and infectious titer was determined by an in situ 
infectivity (MAGI) assay (19). Superuatants with titers of 2.1  x 
10  s infectious units/ml  were filtered through a 0.45-micron filter 
and aliquots were stored at -70~  Normal human PBLs purified 
on Ficoll-Hypaque gradient  were prestimulated with 1% PHA 
(HA15; Wellcome, Beckenham, UK) and 30 U/ml human recom- 
binant IL-2  in RPMI 1640 medium containing 20% FCS, 100 U/ml 
penicillin, 100 #g/ml streptomycin, and 2 mM t-glutamine. After 
3 d, PBL were incubated for 4 h with HIV-1 in the presence of 
10/zg/ml Polybrene (Sigma Chemical Co.). Infections were stan- 
dardized by incubating PBLs with cell-free  virus supernatants con- 
taining 100 ng of p24 core protein/5  x  106 cells as measured by 
an ELISA following the manufacturer's recommendations (NEK- 
060; DuPont, Boston, MA). After virus infection, cells  were washed 
in PBS and resuspended in  10 ml of fresh RPMI  1640 medium 
containing 20% FCS, 20 U/ml IL-2, 100 U/ml penicillin, 100/zg/ml 
streptomycin, and 2 mM t-glutamine.  Noninfected control PBL 
were cultured under identical conditions. After infection, the cells 
were cultured for 8 d and lysed in SDS-PAGE sample buffer at a 
density of 2  x  lff cells/ml. Cell lysates were boiled for 5 rain and 
stored at -20~  until use. Recombinant HIV-1 gag proteins were 
obtained through the NIH AIDS Research and Reference  Program. 
HIV-1 SF2 p25/245 gag contained the gag 24 protein (20). HIV- 
1/IIIB  Gag4 contained the p17 COOH terminus, beginning  at 
amino acid position  146, all of p24, and the p15 NH2 terminus 
(Repligen Corp., Cambridge, MA). As positive control sera, HIV- 
IIIIB p17-specific  and p24 specific  polyclonal sheep antibodies (21), 
monoclonal antibodies to p24 (22), gp41 (22), and gpl20 (23), and 
a HIV-1 gag p17-reactive human  reference serum F06 from the 
Centers for Disease Control (Atlanta, GA) were used. Gel-purified 
recombinant HTLV-I gag p24 was kindly provided by Dr. Chung- 
ho Hung (Cambridge Biotech, Worcester, MA). 
Western Blot Analysis.  500 ng of recombinant TAL-H protein 
in 10/zl/well was separated by SDS-PAGE and electroblotted to 
nitrocellulose (24). Nitrocellulose strips were incubated in 100 mM 
Tris, pH 7.5, 0.9% NaC1, 1% Tween 20, and 5% skim milk, with 
antibodies (at a 1,000-fold dilution unless otherwise indicated) for 
1 h at room temperature. For detection of rabbit antibodies, after 
washing, the strips were incubated with horseradish peroxidase--con- 
jugated goat anti-rabbit  IgG (Boehringer Mannheim Corp., Indi- 
anapolis, IN). For detection of human antibodies, after washing, 
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and, subsequently with horseradish peroxidase-conjugated avidin 
(Jackson ImmunoResearch Laboratories, West Grove, PA). In be- 
tween the incubations the strips were vigorously washed in 0.1% 
Tween-20, 100 mM Tris, pH 7.5, and 0.9% NaC1. The blots were 
developed with a substrate composed of 1 mg/ml 4-chloronaphthol 
and 0.003% hydrogen peroxide. 
Stimulation of PBLs.  Peripheral blood mononuclear cells were 
isolated from heparinized venous  blood on Ficoll-Hypaque  gradient 
and resuspended  in RPMI 1640 medium, supplemented  with 10% 
FCS, 2 mM L-glutamine,  100/IU/ml penicillin, and 100/zg/ml gen- 
tamicin. 105 cells were incubated in each well of a microtiter plate 
using six parallel samples. Recombinant TAL-H  was added in an 
optimal concentration of i/zg/ml. Negative control and positive 
control cultures (containing 10/zg/ml concanavalin A) were in- 
cluded in each experiment. The plates were incubated at 37~  in 
a humidified atmosphere with 5%  CO2 for 72 h.  The cultures 
were pulsed with 0.4/zCi[3H]TdR 8 h before termination. Cells 
were harvested and [3H]TdR  incorporation was measured as ear- 
lier described (25). The results were expressed in cpm as mean _+ 
SE of six parallel cultures. Statistical analysis  was performed with 
Student's t test. 
Immunohistochemistry.  Formalin fixed (10% formaldehyde in 
PBS) and paraffin-embedded  sections of human postmortem brain 
tissue without neurological  disorder was stained  with control preim- 
mune rabbit serum, anti-TAL-H immune rabbit serum 169 (13), 
anti-glial fibfillary  acidic  protein (GFAP) rabbit serum (DAKO, Glos- 
trup,  Denmark) or antigalactocerebroside monoclonal antibody 
(Boehringer Mannheim Corp.) at dilutions of 1:5,000. Slides were 
developed using biotinylated goat anti-rabbit  IgG or goat anti- 
mouse IgG, alkaline  phosphatase-conjugated  streptavidin, and sub- 
strate (all from DAKO). 
Primary Brain Cell Cultures and Immunofluorescence Studies.  Pri- 
mary brain cell cultures were prepared from cerebral hemispheres 
of 2-d-old B10.A mice, as earlier described (26). After 7 d in cul- 
ture, cells were fixed  with 1% paraformaldehyde  in 50 mM Tris/150 
mM NaC1 and permeabilized with 0.25% Triton X-100 in 0.5 M 
Tris, pH 7.4, and stained  with Ab 169 or myelin  basic  protein (MBP)- 
specific rabbit  serum (DAKO). Staining was obtained using a 
horseradish peroxidase-conjugated  swine anti-rabbit antibody and 
4-chloronaphthol substrate as described for Western blots. Cell 
type-specific  expression of TAL and MBP was investigated  by two- 
color immunofluorescence. TAL was  detected by Ab  169  and 
rhodamine-conjugated anti-rabbit goat antibody while MBP was 
visualized using an MBP-specific  rat monoclonal antibody (IgG1; 
Serotec Ltd., Oxford, UK) and FITC-conjugated goat anti-rat an- 
tibody. 169 preimmune rabbit serum with rhodamine-conjugated 
goat anti-rabbit  secondary antibody and a rat monoclonal anti- 
body  to  human  IFN-~  (IgG1; Serotec Ltd.)  with  an  FITC- 
conjugated goat anti-rat secondary  antibody were used as negative 
controls. 
Sequence Analysis.  Amino acid sequence homologies were ana- 
lyzed using the University  of Wisconsin Genetics  Computer Group 
(GCG) Software (27). The nucleotide sequence of the TAL-H  gene 
has been submitted to the GenBankTM/EMBL  Data Bank with ac- 
cession number L19437 (13). 
Results 
Expression of TAL-H Protein in Oligodendrocytes.  Expression 
of TAL is regulated in a developmental and tissue-specific 
manner (28,  29).  It is a pivotal enzyme of PPP that shows 
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maximal activity in the developing nervous system at a period 
of active growth and myelination (30). Identification of  TAL- 
producing cells has now become feasible by cloning of the 
human TAL cDNA, production of  recombinant TAL-H pro- 
tein, and generation of specific antibodies. Antibodies 169 
and 170 are highly specific for the 38-kD TAL-H protein (13). 
Immunohistochemical  analysis of postmortem sections revealed 
that expression  of TAL-H is specific for oligodendrocytes in 
the human brain (Fig. 1). Localization of TAL-H to oligoden- 
droglia was confirmed by parallel staining for galactocerebro- 
side (concordant staining pattern with TAL-H; not shown) 
and GFAP (astrocyte-specific discordant staining pattern rel- 
ative to TAL-H; Fig. 1 C). TAL is detectable in other mam- 
malian species, including the mouse, by using the human 
TAL-H probes (13). Therefore, oligodendrocyte-specific ex- 
pression  was further investigated in murine brain cell cul- 
tures (26).  Concordant expression  of TAL-H and MBP in 
the  oligodendroglia  was  demonstrated  by  simultaneous 
staining with TAL-H-specific rabbit antibody 169 and a MBP- 
specific  rat  monoclonal  antibody  using  two-color  im- 
munofluorescence (Fig. 2, B and C). As a negative control, 
cultures were simultaneously stained with 169 preimmune 
rabbit serum and a rat monoclonal antibody to human IFN-B 
(Figs.  2, D  and E). Anti-TAL-H and anti-MBP antibodies 
showed an identical staining pattern of oligodendrocytes and 
of their processes,  indicating that myelin sheaths may also 
contain the TAL-H protein. No TAL-H expression  was de- 
tected in neurons and astrocytes. 
Detection of TAL-H-specific  Antibodies in Patients with MS. 
Since oligodendrocytes are selectively destroyed in patients 
with MS, the possibility that TAL-H is involved as an au- 
toantigen in this process was investigated. Sera from 171 pa- 
tients with immune disorders  and sera of 101 control blood 
donors was studied by Western blot analysis. Seropositivity 
was based  on immunoreactivity to  a  22-kD  recombinant 
TAL-H protein (500 ng of gel-purified TAL-H protein/lane) 
at serum dilutions of 1:100 or higher. Presence  of TAL-H 
autoantibodies was highly specific for MS. Sera of 25/87 pa- 
tients with MS and of 1/32 patients with ECG reacted with 
recombinant TAL-H protein (Fig. 3). TAL-H-specific anti- 
bodies were not detected in other autoimmune patients in- 
cluding 19 with SJS and 25 with SLE and in 101  control 
blood donors (including 77 healthy subjects and 24 patients 
with other neurological diseases). Thus, detection of TAL-H 
autoantibodies in patients with MS is a highly significant 
finding as compared with control and other autoimmune dis- 
ease groups (p <0.001,  using chi-square test).  No correla- 
tion was found between TAL-H seropositivity and immuno- 
globulin concentrations in the sera of seven patients with MS 
and four control donors (data not shown). 
Most patients with MS have a disease course characterized 
by relapses and remissions, termed relapsing/remitting (R/R) 
MS. A minority of  patients have a primarily chronic progressive 
disease (CP). Many of the R/R  patients will, nevertheless, 
eventually enter a phase of secondary progressive  evolution 
of symptoms. As shown in Table 1, presence of TAL-H anti- 
bodies was independent of the duration or clinical phase of 
the disease. 13/17 cerebrospinal  fluid (CSF)  samples  from Figure  1.  Frozen sections of human post- 
mortem brain tissue without neurological  dis- 
order was stained  with control  preimmune  rabbit 
serum (A), anti-TAbH  immune  rabbit serum 169 
(B), and anti-GFAP  rabbit serum (C). Slides  were 
developed using biotinylated  goat anti-rabbit 
lgG, peroxidase-conjugated  streptavidin,  and sub- 
strate and counterstained  with hematoxylin.  For- 
malin fixation  (10% formaldehyde  in PBS) causes 
shrinking of cytoplasm and  halo formation 
around  oligodendrocytes.  While  GFAP  is specific 
for astrocytes,  expression  of  TAL-H  is specific  for 
oligodendroglia.  Original  magnification, x400. 
TAL-H  seropositive  MS  patients  contained  antibody  to 
TAL-H. Two of three additional CSF samples from MS pa- 
tients with no available serum specimen also contained TAL-H 
antibodies. Thus, antibodies to TAL-H were noted in a total 
of 15/20 CSF samples from patients with MS. By contrast, 
TAL-H antibodies were absent in nine CSF samples  from 
patients with other neurological diseases. Representative anal- 
ysis of serum and CSF samples is shown in Fig. 3.  While 
the amount of TAL-H antibodies was 5-10-fold lower in the 
CSF than serum of corresponding patients, the concentra- 
tion of TAL-H antibodies based on the total Ig content was 
enriched 50-100-fold in the CSF. 
Recombinant TAL-H protein used in these studies was gel- 
purified by electroelution in two cycles to exclude possible 
contamination with bacterial proteins. Antibodies 169 and 
170 showed no reactivity with bacterial protein lysates. This 
indicated that the gel-purified recombinant TAL-H protein, 
used for immunization of rabbits  and testing of seroactivity 
of the patients, was essentially free of bacterial proteins. Along 
the same line, TAL-H positive human sera demonstrated high 
affinity and specificity to the recombinant protein and showed 
no reactivity to bacterial proteins (Fig. 4). TAL-H specificity 
of MS sera was further confirmed by reactivity to a 38-kD 
functional TAL-H protein that had been purified by binding 
of a subsequently removed GST leader to glutathione-coated 
agarose  beads  (data not  shown).  The results  suggest that 
TAL-H is an MS-specific autoantigen and TAL-H autoanti- 
bodies may be an important and pathogenetic factor in MS. 
Stimulation of  PBL Proliferation by TAL-H.  In addition to 
increased amounts of immunoglobulins in the CSF and demye- 
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Figure  2.  Detecti•n•fTALexpressi•ninprimarybraince••cu•turesfr•ma2-d-••dmouseembry•withTAL-H-s•eci•crabbitantib•dy•69.Expres- 
sion of TAL was specific for cells with multiple arc-shaped processes, which is characteristic  of cultured oligodendrocytes. (A) staining was obtained 
using a horseradish  peroxidase-conjugated swine anti-rabbit antibody and 4-chloronaphthol substrate  as described for Western blots. Using two-color 
immunofluorescence,  an identical pattern of oligodendroglia-specific  expression of TALH (B) and MBP (C) was noted. TADH protein was detected 
by antibody 169 and rhodamine-conjugated anti-rabbit goat antibody whereas  MBP was visualized using an MBP-specific rat monoclonal antibody 
and FITC-conjugated goat antl-rat antibody. Red fluorescence images obtained with rhodamine conjugated secondary antibodies and green fluorescence 
images obtained with FITC-conjugated secondary antibodies were separately photographed. 169 preimmune serum  and rhodamine-conjugated goat 
anti-rabbit secondary antibody (D) and a rat monoclonal antibody to human IFN-3 and FITC-conjngated goat anti-rat secondary antibody (E) were 
used as negative  control for staining of TALH and MBP,  respectively. Original magnification,  x625. 
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1655  Banki et al. Table  1.  D~'sease  Data of TAL-H Autoantibody Positive 
MS Patients 
Patient  Age/sex  Dx duration  Dx type 
VAS  26/F  4  yr  IL/R 
NAG  23/M  12  mo  IL/R 
ROB  32/M  1 mo  A 
GAU  36/F  15  mo  R/R 
FIN  42/F  10 yr  CP 
ADE  23/F  2  mo  A 
DILl  35/M  6  mo  A 
MOO  45/M  12  yr  IL/R 
LEI  57/F  23  yr  CP 
BUR  39/F  11  yr  R/R 
LEA  46/M  11  yr  S 
JOS  47/F  8  yr  CP 
PAS  41/F  6 yr  IL/IL 
ASH  55/F  6  yr  CP 
COL  45/F  1 yr  R/IL 
MCG  36/F  10 yr  R/R 
MCC  31/F  8  mo  IL/IL 
DIO  22/M  3  yr  CP 
GIU  53/F  2 yr  R/IL 
TUN  N/A  10 yr  CP 
THO  33/F  2 yr  R/R 
SHO  81/F  54  yr  S 
GILO  82/F  25  yr  S 
MS-H  38/F  8  yr  CP 
MS-C  66/M  10 yr  CP 
MS-IL  38/F  5 yr  R/R 
MS-M  N.A.  N.A.  CP 
JAB  40/F  8 yr  R/R 
LAK  37/F  3  yr  R/IL 
KUB  48/F  20 yr  CP 
Figure  3.  Western blot analysis of immunoreactivity of sera from pa- 
tients with MS against recombinant TADH protein. TAL-H positive sera 
are indicated by patients' initials; 1, 2, 3, and C are normal human sera; 
169, TAL-H-specific  rabbit antibody; unmarked lanes indicate TAL-H  nega- 
tive sera of MS patients. CSF (indicated by/CSF extension) and sera were 
tested in parallel from patients MS-C, MS-M, MS-R, ROB, and GAU, 
respectively. 
linating  lesions,  accumulation  of activated T  cells has been 
demonstrated around early MS lesions. It is generally accepted 
that autoreactive T  cells in patients with MS recognize com- 
ponents  of the  myelin  sheaths  (1).  To investigate whether 
TAL-H may be a target of autoreactive T  cells,  its effect on 
proliferation of PBLs was evaluated.  Highly purified recom- 
binant  TAL-H antigen  was used  in  these  studies  to ensure 
that the responses detected are not directed to any other my- 
elin protein.  Addition  of I  #g/ml  TAL-H significantly in- 
creased proliferation  of lymphocytes from  11 patients  with 
Dx, diagnosis; M,  male; F,  female; A,  acute; S,  stable. 
MS  (p <0.001,  Table 2).  The  stimulation  index  varied be- 
tween  1.4- and  10.3-fold among the patients.  Lymphocytes 
were incubated  in  the presence of 10%  autologous  serum. 
Heat-inactivation  of autologous  serum or use of 10%  FCS 
had  no  significant  effect  on  the  proliferative  responses  to 
TAL-H. As shown in Fig. 5, the effect of TAL-H was confined 
to a subset of lymphocytes that showed intense blastogenesis 
and  aggregation.  By  contrast,  aggregation  (Fig.  5  C)  or 
proliferation  of normal  lymphocytes was  not  significantly 
stimulated in the presence of TAL-H (Table 2). Proliferation 
of lymphocytes from MS patients was not affected by 5/~g/ml 
GST protein purified from the same E. coli strain as TAL-H 
(data  not  shown). 
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human autoantibodies from pa- 
tients  BEN  (ECG) and  GAU 
(MS). Sera BEN and GAU strongly 
react with TAL-H-containing  in- 
duced bacterial lysates (i) but do 
not react  with control  bacterial ly- 
sates (c). 
Amino Acid Homologies and Immunological Cwssreactivity be- 
tween TAL-H and Retroviral Core Proteins.  Molecular mim- 
icry has been  suggested  to play a key role in breaking  the 
tolerance towards self-proteins and induction of autoimmune 
disease  (1,  31).  Antibodies  crossreactive with  a  number  of 
viral proteins have been described in patients  with MS (1). 
In the  amino  acid  sequence  of TAL-H,  two  clusters  that 
showed  significant  homology to  core  proteins  of human 
retroviruses  were identified  (Fig.  6).  An NHa-terminal  50- 
amino  acid long  segment  of TAL-H contains  a  region of 
limited homology to the HIV-1 gag p17 protein (32). The 
possibility of crossreactive antigenic epitopes between TAL-H 
and HIV-1 gag p17 was raised by immunoreactivity of anti- 
body 169 with gag p17 and gag precursors p57 and p47 in 
protein lysate of HIV-l-infected PBL (Fig. 7 A). HIV-l-en- 
coded proteins in the lysate of infected PBL were identified 
with a panel of  HIV-1 gag p17, gag p24, env gp41, and gp120- 
specific antibodies  (data not shown).  Presence of crossreac- 
tive epitopes in TAL-H and HIV-1 gag p17 was further sub- 
stantiated by binding of HIV-1 gag p17-reactive human F06 
(Fig.  7 B)  and gag pl7-specific sheep antibodies  to recom- 
binant TAL-H (Fig. 7 C). Potential significance of four con- 
secutive  amino  acid  residues,  Ala-Asp-Thr-Gly  (AI~G), 
shared  between  TAL-H  and  HIV-1  gag p17  (Fig.  6)  was 
demonstrated by use of Gag4,  a recombinant  protein  con- 
taining  the p17  COOH  terminus,  all  of p24,  and  the p15 
NH2 terminus,  while lacking the first  145  amino acids in- 
cluding the ADTG residues at positions 120-123. As shown 
Table  2.  Pwliferation  Responses to Recombinant TAL-H by PBLs of MS Patients and Controls 
Patient  Age/sex  Dx duration  Dx type  TAL-H Ab 
Proliferation  response  of PBLs 
Control  TAL-H  S.I. 
JAB  40/F 
LAK  37/F 
KUB  48/F 
PCA  41/F 
TEV  39/F 
AAB  31/M 
JWA  44/M 
ANB  57/F 
GIB  49/M 
CPI  28/F 
JKO  59/F 
Mean  _+  SEM 
Controls 
PRO  27/F 
GIT  26/M 
HAB  64/F 
PEG  44/F 
EST  26/F 
Mean  _+  SEM 
8  yr  R/R  + 
3 yr  R/R  + 
20 yr  CP  + 
16 yr  CP  - 
11 yr  R/R  - 
5 yr  R/R  - 
12 yr  R/R  - 
26 yr  CP  - 
19 yr  CP  - 
3 yr  R/R  - 
23 yr  CP  - 
73  +  10  180  +  15  2.5 
66  _+  13  207  +_  34  3.1 
48  +  3  138  _+  28  2.9 
53  _+  6  374  _+  28  7.1 
49  +  6  504  +  47  10.3 
57  _+  7  178  _+  15  3.1 
75  _+  16  244  _+  45  3.3 
80  +  10  110  +_  13  1.4 
72  _+  7  337  +  121  4.7 
77  +_  7  209  _+  23  2.7 
43  +_  6  195  +  31  4.5 
4.15  +_  0.8* 
174  _+  37  177  +  37  1.0 
89  _+  21  209  _+  64  2.3 
79  +_  5  79  +_  7  1.0 
76  +  24  55  _+  21  0.7 
42  +  20  60  +_  15  1.4 
1.3  +  0.3 
Cell proliferation was measured in the presence of 10% autologous serum without (control) or with 1/xg/ml recombinant TAL-H protein (TAL-H). 
Data are expressed as mean cpm _+  SE of six parallel cultures. 
* Significant stimulation: p <0.001. 
Dx, diagnosis; M, male; F, female; A, acute; S, stable; S.I.,  stimulation index. 
1657  Banki  et al. Figure  5.  Stimulation of aggregate  formation of PBLs from a patient with MS (GIB) by recombinant  TAL-H. 10  s cells were incubated  without 
(A) or with  1 #g/ml TAL-FI for 72 h  (B). C  shows lymphocytes  from a normal donor (BRO) incubated  for 72 h with 1 #g/ml TAL-H. Original 
magnification,  ￿ 
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in Fig. 7 C, the polyclonal HIV-1 gag p17-specific sheep an- 
tibody showed immunoreactivity with both TAL-H and Gag4 
but failed to react with gag p24. Alternatively, the anti-HIV 
gag p24 antibody displayed specific  reactivity to the Gag4 
construct and gag p24 but failed to react with TAL-H. Anti- 
body 169, recognizing the full-length gag p17 protein, failed 
to react  with  the  truncated  polypeptide in  the  Gag4  con- 
struct.  These results indicate that  the crossreactive epitope 
with TAL-H is contained within the NH2-terminal segment 
of HIV-1 gag p17. The four consecutive amino acids, ADTG, 
present  in both TAL-H  and the NH2-terminal  segment  of 
HIV-1 gag p17 are likely to represent the core of crossreac- 
tive epitopes. 
To determine the significance of amino acid sequence ho- 
mologies between TAL-H and HTLV-I proteins,  reactivity 
of HTLV-I antibodies to recombinant TAL-H was evaluated. 
HTLV-I-specific antibodies including rabbit antisera raised 
against HTLV-I virion lysate and human sera from five HTLV- 
I-infected ATL patients  reacted with  recombinant  TAL-H 
protein (representative Western blots are shown in Fig. 8 A). 
Conversely, TAL-H antibody 169 crossreacted with a recom- 
binant  HTLV-I gag p24 protein at  a 1:1,000  dilution  (Fig. 
8 B). These data indicated the presence of crossreactive anti- 
genic epitopes in TAL-H and HTLV-I gag p24.  Three sets 
of three consecutive amino  acids,  Gln-Leu-Lys,  containing 
two polar  and highly  charged  amino  acids  (Gin  and Lys), 
present in both the transaldolase-associated  repetitive dement 
(TARE)-encoded  segment  of TAL-H  (residues  17-19)  (13) 
and HTLV-I gag (residues 45-47) (33), Leu-Ala-Ala (residues 
50-52 in TAL-H and residues 248-250 in HTLV-I gag),  as 
well as Lys-Leu-Leu (residues 257-259 in TAL-H and 312-314 
in HTLV-I gag) are likely to be the core of crossreactive epi- 
topes.  Sera  of five of the TAL-H  seropositive  MS patients 
TAL-H  17  QLKQFT'~,/VADT 28 
HTLV-I  gag  p24  230  ....  QANNP  LR.~EYQQLWLAAFAALPOSAKDPSWASIL  LEEPY  274 
o  ,llll 
TAL-H  30 DFHAIDEYKPQDATTNPS.,.LILAA.AQMPA  ..........  YQELVEEA  65 
2,5  .......  ....  .................. ....  ,oo  ........ 
66  IAYGRKLGGSQEDQIKNAIDKLFVLFGAEILKKIP.GRVSTEVDARLSFD  114 
316  Q~J~GHTNSPLGDMLRACQTWTPKDKTKVL  344  22%  (40%) 
115  KDAMVARARRLIELYKEAG..ISKDRI...  139 
TAL-M 
H~V p17 
HTLV-I  g24 
TAL-H 
12  ESALDQLKQFTTVVADTGDFMAIDEMKPQDATTNPSLILAAA~MPAYQELV  62 
i  I  llll  I  i  I 
106  EEQNKSKKKAQQA2L~DTGHSNQVSQNYPIVQNIQC-QMVHQAISPRTLNAWV  156  18% 
299  LRSLAYSNANKEOQKLLQARGHTNSPLGDMLRACQTWTPKDKTKVL  344  24% 
fl  Irr  I  I  I I  l 
243  IKALAGCDFLTISPKLLGELLQDNA/(LVPVLSAKAAQASDLEKIHL  288 
Figure  6.  Amino  acid  sequence  homologies  detected  with the GAP pro- 
gram of the UWGCG Software (27) between TAL-H (13) and gag/core 
proteins of  HTLV-I  (33) and HIV-1 (32). Percent  homologies  and position 
of identical residues  are shown  for each  sequence  alignment ( I  ). Percentage 
(in parenthesis) and position of functionally similar amino acids between 
TAbH and HTLV-I gag p24 are also indicated (:). 
1659  Banki  et al. Figure 7.  Immunological crossreactivity  between recombinant TAL-H and HIV-1 gag p17 proteins by Western blot analysis. Protein lysates from 
2  x  105 control and HIV-l-infected PBL per lane (A), 38-kD full-length affinity-purified  recombinant TAL-H protein (500 rig/lane, B), and FIIV-1 
Gag4, HIV-1 gag p24, and TALH (500 ng of the indicated protein/lane, C) were separated by SDS-PAGE, transferred to nitrocellulose, and incubated 
with antibodies as earlier described. TAL-H  antibody 169 was added at a 1:10,000 dilution to blots of A and B, while it was used at a 1:1,000 dilution 
in C allowing detection of TAL-H degradation products. Immunoreactivities of preimmune antibody 169, and HIV-1 gag p17- and gag p24-specific 
antibodies were assessed at a 1:1,000  dilution, while human control serum and F06 serum from an HIV-l-infected donor were added at a 1:100  dilution. 
(ADE,  BUR, JOS,  ROB,  and VAS) and of the  one ECG 
patient  (BEN) also reacted with recombinant HTLV-I gag 
p24 (data for BEN are shown in Fig. 8).  Thus,  autoantige- 
nicity  of TAL-H  could  explain  the  presence  of HTLV-I 
gag-reactive autoantibodies in a subset of patients with MS 
(34-37) and, alternatively,  molecular mimicry between HTLV- 
I and other retroviral core proteins may trigger autoimmu- 
nity toward  TAL-H. 
Discussion 
Demyelination in MS results from damage to the myelin 
sheath which provides a multimembrane insulation for neu- 
ronal axons. Loss of the myelin cover leads to diminished con- 
duction velocity of axons of motor and/or sensory pathways 
causing a wide range of neurological abnormalities (1).  My- 
elin sheaths are formed by oligodendrocytes in the CNS. The 
present  study demonstrates  that TAL-H is  expressed  selec- 
tively in oligodendrocytes at high levels.  TAL is a pivotal en- 
zyme of PPP that shows maximal activity at birth and early 
stages of embryogenesis, coinciding with development of the 
nervous system at a period of active growth and myelination 
Figure  8.  Detection  of  crossreactive antigenic  epitopes between recom- 
binant TAL-H  and recombinant HTLV-I  gag p24 proteins by Western blot 
analysis. The 22-kD recombinant TALH protein, composed  of the NH2- 
terminal 140 amino acids, was purified by electroelution from preparative 
SDS-PAGE in two cycles. Recombinant proteins were separated by SDS- 
PAGE and transferred to nitrocellulose  membrane, and incubated  with an- 
tibodies as earlier described. Immunoreactivities  of  TAL-H  Ab169  and sera 
from ECG patient (BEN), and a prototype HTLV-I-infected  patient (ATL) 
with recombinant TAL-H and HTLV-I  gag p24 are shown in A and B, 
respectively. Control serum is from a normal donor. Sera were added to 
Western blot strips at a dilution of 1/100 unless indicated otherwise. 
1660  Transaldolase  and Multiple Sclerosis (30). Another fundamental function of the PPP is to main- 
tain glutathione at a reduced state and, consequently, to pro- 
tect sulfhydryl groups and cellular integrity. Oligodendrocyte- 
specific expression of TAL-H is particularly interesting be- 
cause of a primary involvement of these cells in demyelinating 
diseases of the CNS. Whereas myelin and oligodendrocytes 
do not show significant levels of MHC class II or class I an- 
tigen expression or surface expression of MBP (38, 39), they 
are  sensitive to a direct  attack by activated CD4 + T  cells 
(40). A breakdown of the blood brain barrier  may provide 
a route of entry for otigodendrocyte-specific antibodies. Like- 
wise, antibodies to TAL-H may mediate demyelination by 
attracting microglia and macrophage through their Fc receptors 
and, thus, triggering phagocytosis and antibody-dependent 
cell-mediated cytotoxicity (41). Antibodies to TAL-H were 
detected in a subset of patients with MS. The fact that TAL-H 
antibodies were absent in controls including patients with 
other neurological diseases  as well as in patients  with  sys- 
temic autoimmune diseases such as SLE and SJS indicates that 
autoimmune process targeting TAL-H is highly specific for 
MS.  Further,  antibody to TAL-H was detected in CSF of 
15/20 MS patients.  In comparison to sera, concentration of 
TAL-H antibodies based on the total Ig content was several- 
fold higher in the CSF. An increase in the amount of immu- 
noglobulins in the CSF has been one of the earliest and most 
consistently reproduced findings  that  raised the possibility 
of an immune-mediated  pathogenesis and is routinely used 
as a diagnostic criterion in MS (42). It is intriguing  to con- 
sider the possibility that  an intrathecal  synthesis of TAL-H 
autoantibodies might be connected to oligodendroglia-specific 
expression  of the  protein  and  an  eventual  destruction  of 
oligodendrocytes in MS. In contrast to the presence of high- 
affinity TAL-H autoantibodies, we failed to detect antibodies 
to purified human MBP by Western blot analysis in our pa- 
tients with MS (not shown). This is in accordance with other 
investigators, suggesting that MBP-directed immunity is pri- 
marily T  cell mediated  (1,  43). 
There are a number of possible mechanisms for genera- 
tion of TAL-H-specific autoantibodies. First, molecular mim- 
icry, that is, infection by an exogenous agent such as a retrovirus 
with crossreactive epitopes, may trigger TAL-H antibodies. 
We and many other investigators have not found conclusive 
evidence for the involvement of exogenous retrovirus in human 
autoimmunity (34). Nevertheless, it is possible that a retrovirus 
responsible for provoking autoimmunity has been cleared from 
the CNS,  so the absence of viral particles  or DNA is not 
conclusive (44).  Core proteins are a usual target of the im- 
mune response during viral infections. Because of its oligo- 
dendrocyte-specific expression and presence of crossreactive 
autoantigenic epitopes in its NH2-terminal retrotransposon- 
encoded region, TAL-H may be a key target of HTLV-I and 
other  retroviral-initiated  autoimmunity.  Since  sera  of all 
HTLV-I-infected individuals tested show crossreactivity with 
TAL-H, its involvement in another demyelinating disease of 
the CNS, HTLV-I-associated myelopathy or tropical spastic 
paraparesis  (TSP), is also possible (45, 46). Presence of cross- 
reactive epitopes between HIV-1 gag p17 and TAL-H may 
be related to neurological manifestations of AIDS (47). Thus, 
infections by retroviruses carrying a TAL-H related core pro- 
tein may potentially trigger an autoimmune attack against 
oligodendrocytes. Although TAL-H is located primarily in 
the  cytosol,  antigen  peptides  of cytosolic proteins  can be 
processed and associated intracellularly with MHC molecules 
and exported to the cell surface (48, 49). Thus, TAL-H epi- 
topes presented on the cell surface may become targets  of 
immune responses originally directed to a crossreactive viral 
core protein. The consequent destruction of target cells, such 
as oligodendrocytes, would release  more TAL-H from the 
cytoplasm. The released TAL-H could then further stimu- 
late lymphocytes already primed by the viral antigen,  thus 
perpetuating  the immune response long after the elimina- 
tion  of the  viral  infection.  Since expression  of TAL-H  is 
confined to the oligodendroglia in the brain,  the resultant 
autoimmune process could lead to a selective destruction of 
oligodendrocytes. 
Second, autologous proteins may also trigger an immune 
response upon presentation  in large quantities,  usually ac- 
companying extensive tissue destruction (50, 51). This mech- 
anism, however, seems unlikely. Whereas TAL-H constitutes 
1-3 % of the total protein content of oligodendrocytes, MBP 
makes up as much as 30%  of the CNS myelin (52).  Thus, 
generation of antibodies secondary to tissue injury would  just 
as likely result in antibodies to the highly charged MBP pro- 
tein as to TAL-H. However, antibodies to MBP are absent 
in patients  with  MS. 
Existence of cell-mediated immunoreactivity to TAL-H in 
patients with MS was substantiated by stimulation of prolifer- 
ation and aggregate formation of peripheral blood lympho- 
cytes in response to recombinant TAL-H. Levels of prolifera- 
tive responses to TAL-H were higher than those in response 
to other myelin antigens  (53).  The results clearly indicate 
that  TAL-H  may be a prominent  target  of both cell-  and 
antibody-mediated  autoimmunity  in  patients  with  MS. 
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